Please input keywords
신약의 조기 출시를 위한 오픈 이노베이션
Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.
Collaboration Models
Various drug modalities
Disclosed Partners
Worldwide antibody assets or platform partners include Gilead, Merck KGaA, Janssen, Xencor, ADC Therapeutics, Neurocrine Biosciences, Radiance Biopharma, RemeGen and BeiGene.